Nuvalent, Inc. (NUVL)
Nuvalent (NUVL) sees significant social media buzz with a 646% surge in social dominance and a 203% increase in sentiment. Recent posts highlight potential government supply deals and Q4 performance reviews, alongside analyst coverage initiation for a related company with NUVL mentioned.
About Nuvalent, Inc.
Nuvalent, Inc. is a biopharmaceutical company focused on developing and commercializing therapies.
Nuvalent, Inc. uses the ticker $NUVL for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Nuvalent, Inc. (NUVL) social dominance is up 646.67% from the previous week.
- Nuvalent, Inc. (NUVL) sentiment is up 203.03% from the previous week.
- Nuvalent, Inc. (NUVL) creators is up 10.14% from the previous week.
- Nuvalent, Inc. (NUVL) engagements is up 27.03% from the previous week.
- Nuvalent, Inc. (NUVL) mentions is up 15.07% from the previous week.
Price: $102.20
Price 24-Hour Time-Series Raw Data
The stock recently hit a 52-week and all-time high but has seen a slight decrease, likely due to profit-taking as social sentiment has not yet fully translated into sustained price appreciation.
24-Hour: 1.41% 7-Day: -0.73% 30-Day: -1.94%
1-Year High: $112 on 2026-01-22
1-Year Low: $59.30 on 2025-04-08
AltRank: [-----]
AltRank 24-Hour Time-Series Raw Data
Nuvalent, Inc. (NUVL) is currently AltRank #1,554 based on combined combined social and market metrics
Daily Average: [-----]
[--] Week: [-----] [----]
[--] Month: [-----] +877
[--] Months: [-----] +742
[--] Year: [-----] +678
1-Year High: [-----] on 2025-08-07
1-Year Low: [--] on 2025-11-01
Galaxy Score: [--]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] +10
[--] Months: [--] [---]
[--] Year: [--] [---]
1-Year High: [--] on 2025-08-22
1-Year Low: [--] on 2025-03-28
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Week: [-----] +27%
[--] Month: [------] -46%
[--] Months: [-------] +6.80%
[--] Year: [---------] -29%
1-Year High: [-------] on 2025-11-17
1-Year Low: [---] on 2025-03-31
Engagements by network (24h): News: [--] YouTube: [--] Reddit: [--] X: [-----]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Week: [---] +15%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-04-03
Mentions by network (24h): News: [--] YouTube: [--] Reddit: [--] X: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning Nuvalent, Inc. (NUVL) in the last [--] hours which is no change from in the previous [--] hours
Daily Average: [--]
[--] Week: [--] +10%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-04-03
The most influential creators that mention Nuvalent, Inc. in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Andre_AGTC | [--] | [-----] | [--] | [---] |
| @BuyTheUgly | [--] | [--] | [--] | [--] |
| @stocket_rocket | [--] | [--] | [--] | [--] |
| @Ella55005 | [--] | [--] | [--] | [--] |
| @Rayan23397 | [--] | [--] | [--] | [--] |
| @Trade_Pro04 | [--] | [--] | [--] | [--] |
| @Trader_House04 | [--] | [--] | [--] | [--] |
| @Barmon81512 | [--] | [--] | [--] | [--] |
Sentiment: 40%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 40%
Daily Average: 71%
[--] Week: 100% +67%
[--] Month: 30% -39%
[--] Months: 30% -70%
[--] Year: 30% -32%
1-Year High: 100% on 2025-03-17
1-Year Low: 11% on 2025-09-23
Most Supportive Themes:
- Insider Buying: (40%) Insiders are showing significant conviction by acquiring shares, suggesting a positive outlook on the company's future prospects.
- Company Updates and Mentions: (30%) Nuvalent is being mentioned in various updates, including potential government supply deals and Q4 performance reviews, indicating active interest and development.
Most Critical Themes:
- Profit-Taking After Highs: (70%) The stock experienced a slight decrease after hitting a 52-week and all-time high, likely due to investors taking profits.
Social Dominance: 0.00299%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00299%
Daily Average: 0.00689%
[--] Week: 0.00224% +0.00194%
[--] Month: 0.0039% -0.0004000000000000002%
[--] Months: 0.0039% -0.0002999999999999999%
[--] Year: 0.0039% -0.0062%
1-Year High: 0.034% on 2025-06-28
1-Year Low: 0.0013% on 2025-10-12
Market Dominance: 0.009%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.009%
Daily Average: 0%
1-Year High: 0.372% on 2026-02-06
1-Year Low: 0.0076% on 2025-03-11
Market Cap: $7,939,673,253
Market Cap 24-Hour Time-Series Raw Data
Current Value: $7,939,673,253
Daily Average: $6,315,717,224
[--] Week: $7,953,651,551 -0.57%
[--] Month: $7,953,651,551 -1.80%
[--] Months: $7,953,651,551 +50%
[--] Year: $7,953,651,551 +44%
1-Year High: $8,696,831,060 on 2026-01-22
1-Year Low: $4,247,188,614 on 2025-04-08
Top Nuvalent, Inc. Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"Citizens🏁 $IMMP and said We are initiating coverage of Immutep Limited with a Market Outperform rating and $6 price target based on a revenue and earnings multiple analysis. $MRK AUTL ALLO ANL SMMT DSNKY AZN BMY $NUVL Citizens added Eftilagimod alpha ('efti') has demonstrated strong clinical immunostimulatory effects that potentiate and expand the effectiveness of established checkpoint inhibitor (CPI) therapies across multiple large Phase [--] studies. The company is currently conducting a large randomized Phase [--] study evaluating the combination of efti + pembro/chemo versus pembro/chemo"
X Link @Quantumup1 2026-02-17T12:04Z [----] followers, [----] engagements
"Q4 Update top 10+10 $MDGL NASH $AXSM CNS MDD $XENE CNS seizures $KRYS GT DEB $MIRM IBAT rare $RVMD RASmuti $CRNX endocrine $BBIO ATTR $SRRK TGFb $ALNY RNAi $CPRX $ABEO $CORT $KYMR $NUVL $QURE $IMCR $NBIX $VKTX $MLYS Update top 10+10 (after $VRNA BO) $MDGL NASH $AXSM CNS MDD $XENE CNS seizures $KRYS GT DEB $VKTX metabolic $MIRM IBAT rare $MLTX I&I IL17A/F $SRRK TGFb $ALNY RNAi $RVMD RASmuti $BBIO $CRNX $CPRX $ABEO $KYMR $NUVL $IMCR $ACAD $CORT $NBIX Update top 10+10 (after $VRNA BO) $MDGL NASH $AXSM CNS MDD $XENE CNS seizures $KRYS GT DEB $VKTX metabolic $MIRM IBAT rare $MLTX I&I IL17A/F $SRRK"
X Link @Andre_AGTC 2025-09-30T14:34Z [----] followers, 36.9K engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing